Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,549.80GBp
20 Jul 2018
Change (% chg)

-8.20 (-0.53%)
Prev Close
1,558.00
Open
1,561.20
Day's High
1,561.60
Day's Low
1,538.00
Volume
8,774,063
Avg. Vol
8,805,731
52-wk High
1,632.00
52-wk Low
1,235.20

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.21
Market Cap(Mil.): £75,181.28
Shares Outstanding(Mil.): 4,918.63
Dividend: 19.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 38.75 30.93 32.76
EPS (TTM): 0.39 -- --
ROI: 7.58 15.07 14.61
ROE: 278.84 16.60 16.34

GlaxoSmithKline considers splitting up the group - FT

GlaxoSmithKline Plc is considering a break-up of the group after investors pressed the company's board to spin off its consumer division, the Financial Times reported on Friday.

20 Jul 2018

Deals of the day-Mergers and acquisitions

July 20 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:

20 Jul 2018

GlaxoSmithKline considers splitting up the group: FT

GlaxoSmithKline Plc is considering a break-up of the group after investors pressed the company's board to spin off its consumer division, the Financial Times reported on Friday.

20 Jul 2018

UPDATE 1-GlaxoSmithKline considers splitting up the group - FT

July 20 GlaxoSmithKline Plc is considering a break-up of the group after investors pressed the company's board to spin off its consumer division, the Financial Times reported on Friday.

20 Jul 2018

GlaxoSmithKline considers break-up of the group - FT

July 20 GlaxoSmithKline Plc is considering a break-up of the group after investors pressed the company's board to spin off its consumer division, the Financial Times reported on Friday.

20 Jul 2018

Clamor for GSK shingles shot points to bigger profits

LONDON GlaxoSmithKline is facing "unprecedented" demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought.

25 Jun 2018

Clamour for GSK shingles shot points to bigger profits

LONDON GlaxoSmithKline is facing "unprecedented" demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought.

25 Jun 2018

Clamour for GSK shingles shot points to bigger profits

* Strong demand will mean intermittent shortages through 2018

25 Jun 2018

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

20 Jun 2018

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

20 Jun 2018

Earnings vs. Estimates